Procter & Gamble Health Limited, one of India’s leading names in the vitamins, minerals, and supplements (VMS) segment, announced its financial performance for the first quarter of FY 2025–26, ending June 30, 2025. The company has reported an impressive 20% year-on-year growth in sales, clocking in revenue of ₹333 crore, as disclosed in its press release dated August 1, 2025.

This growth reflects strong business momentum across both domestic and international markets. Profit After Tax (PAT) stood at ₹66 crore, significantly higher than the ₹17 crore posted in the corresponding quarter last year. The improved profitability has been attributed not only to robust sales growth but also to a one-time impairment impact in the base period which had reduced profits last year.

Growth Driven by Strategic Focus and Consumer Relevance

Commenting on the performance, Mr. Milind Thatte, Managing Director of P&G Health India, expressed satisfaction with the company’s ongoing growth trajectory. He said:

"We are pleased with the continued momentum and strong start to the Financial Year 2025-26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities."

The company’s strategic approach is focused on a highly curated brand portfolio that emphasizes quality, trust, and consumer recommendation. Products such as Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion continue to lead in their respective categories.

Key Pillars of Performance

The Managing Director outlined the key strategic levers responsible for the quarter’s stellar performance:

• Brand superiority across product, packaging, communication, retail execution, and consumer value.

• Constructive disruption, driven by scientific innovation and technology.

• Agile and accountable teams focused on operational excellence.

• Improved supply chain execution and expansion in market reach.

These principles have allowed the company to consistently outperform industry averages and build strong engagement with both end consumers and healthcare professionals.

Sales Performance: Domestic and Export Momentum

While the press release doesn’t detail the exact contribution of domestic vs export business, the company attributes growth to a broad-based uptick across both verticals. Domestic demand for wellness and nutritional supplements continues to remain resilient, while the export markets—especially in Asia and the Middle East—have shown renewed growth traction post-COVID recovery.

The company’s VMS portfolio has received positive feedback for its efficacy, reliability, and science-backed formulations, enabling higher brand loyalty among consumers.

Profit Jump: One-Time Factors and Operating Leverage

The surge in Profit After Tax to ₹66 crore, from ₹17 crore in Q1 FY25, marks a remarkable improvement in bottom-line performance. While sales growth contributed significantly, the base quarter had experienced an impairment-related accounting adjustment that had pulled down net earnings.

With that one-time drag absent in Q1 FY26, and the operating leverage from better volume growth kicking in, the company's profit margins have improved, likely aided by efficiency gains and prudent cost controls.

Consumer-Centric and Science-Led Innovation

In line with the company’s global mission to "make life a little better every day", P&G Health continues to invest in innovation driven by science. The quarter saw progress in:

• Product reformulations tailored to Indian dietary and health preferences.

• Digital engagement campaigns aimed at both B2C and B2B stakeholders.

• Medical education programs for doctors and pharmacists highlighting new clinical data.

These efforts are aimed at driving awareness and trust in P&G Health’s products as reliable daily supplements for modern lifestyles.

About Procter & Gamble Health Limited

Procter & Gamble Health Limited is one of India’s largest companies in the Vitamins, Minerals & Supplements (VMS) category. The company markets several well-known brands like:

• Neurobion – for nerve health.

• Livogen – an iron supplement for anaemia and fatigue.

• SevenSeas – cod liver oil and omega-3 products.

• Evion – Vitamin E-based antioxidant for skin and cell repair.

• Polybion – vitamin B complex formulations.

• Nasivion – for nasal congestion relief.

For more details, visit: www.pghealthindia.com

About P&G Global

Procter & Gamble is a global leader in consumer goods with presence in over 70 countries. Its iconic brand portfolio includes Ariel, Pampers, Gillette, Head & Shoulders, Olay, Oral-B, Pantene, Tide, Whisper, and Vicks, among others. The company is known for its high standards of quality, product safety, and innovation.

Investor and Media Contacts

Media Contact (P&G Health):
Paromita Kundu | Email: kundu.p.1@pg.com

Agency Contact – SPAG FINN Partners:
Sarah Rajan | sarah.rajan@finnpartners.com
Desiree Crasto | desiree.crasto@finnpartners.com

Conclusion

The Q1 FY26 results of Procter & Gamble Health Limited reflect the company’s well-structured strategic focus, its understanding of consumer health needs, and its ability to adapt rapidly to changing market conditions. With a 20% jump in revenue and almost fourfold increase in PAT, the company begins the financial year on a strong footing.

As it continues to invest in brand building, innovation, and healthcare engagement, stakeholders can expect sustained growth through FY26, making P&G Health a prominent player to watch in India’s nutraceutical and pharmaceutical landscape.

The Upcoming IPOs in this week and coming weeks are BLT Logistics, Bhadora Industries, Highway Infrastructure, Parth Electricals & Engineering, Jyoti Global Plast, Essex Marine, Aaradhya Disposal Industries.

The Current active IPO are Flysbs Aviation, Cash Ur Drive Marketing, Renol Polychem, B.D. Industries (Pune), NSDL, Takyon Networks, Mehul Colours, M&B Engineering, Sri Lotus Developers & Realty.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.